Scarica l'app Stockscreener
4.075
5.67%
-0.245
Dopo l'orario di chiusura:
4.09
0.015
+0.37%
Precedente Chiudi:
$4.32
Aprire:
$4.28
Volume 24 ore:
53,315
Relative Volume:
0.57
Capitalizzazione di mercato:
$16.39M
Reddito:
-
Utile/perdita netta:
$-21.21M
Rapporto P/E:
-0.125
EPS:
-32.6
Flusso di cassa netto:
$-16.86M
1 W Prestazione:
-6.32%
1M Prestazione:
+7.80%
6M Prestazione:
+11.64%
1 anno Prestazione:
-64.80%
Intervallo 1D:
$4.02
$4.31
Intervallo di 1 settimana:
$4.00
$4.41
Portata 52W:
$1.8001
$20.83
Cingulate Inc Stock (CING) Company Profile
Nome
Cingulate Inc
Settore
Industria
Telefono
(913) 942-2300
Indirizzo
1901 W. 47TH PLACE, KANSAS CITY
Confronta CING con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CING
Cingulate Inc
|
4.075 | 16.39M | 0 | -21.21M | -16.86M | -32.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Cingulate Inc Stock (CING) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-10 | Iniziato | ROTH MKM | Buy |
| 2023-12-22 | Downgrade | Laidlaw | Buy → Hold |
Cingulate Inc Borsa (CING) Ultime notizie
27,323 Shares in Cingulate Inc. (NASDAQ:CING) Acquired by Geode Capital Management LLC - Defense World
Cingulate Inc. Receives Buy Rating Amid Promising Developments in ADHD Treatment CTx-1301 - TipRanks
CING Reports Positive Results for CTx-1301 in Food Effect Study - GuruFocus
Cingulate announces results from high-dose fed/fast study of CTx-1301 - TipRanks
Cingulate Announces Positive Top-Line Results from - GlobeNewswire
Cingulate Announces Positive Top-Line Results From High-Dose (50Mg) Fed/Fast Study Of Lead Asset Ctx-1301 For Adhd - marketscreener.com
Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHD - Yahoo Finance
Cingulate (NASDAQ:CING) Given New $60.00 Price Target at Ascendiant Capital Markets - Defense World
Analysts’ Top Healthcare Picks: Healthequity (HQY), Cingulate Inc (CING) - The Globe and Mail
Cingulate secures $3m to advance once-daily anxiety treatment - Yahoo Finance
Cingulate wins $3M from private foundation to help develop third time-release drug - The Business Journals
CING: 2024 Financial and Operational Results - Yahoo Finance
Cingulate Inc. (NASDAQ:CING) Shares Purchased by Commonwealth Equity Services LLC - Defense World
Cingulate Inc Secures $3M Grant for Anxiety Drug - TipRanks
Cingulate Receives $3 Million Grant from Private Foundation - GlobeNewswire
Revolutionary Once-Daily Anxiety Drug Gets $3M Boost: Targeting $5.5B Market - Stock Titan
Cingulate moves closer to ADHD drug submission By Investing.com - Investing.com South Africa
Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301 - GlobeNewswire
Cingulate Inc’s Strategic Progress and Promising Clinical Results Justify Buy Rating - TipRanks
Cingulate Completes Pre-NDA Meeting With FDA To Discuss New Drug Application For Lead ADHD Asset CTX-1301 - MarketScreener
Cingulate moves closer to ADHD drug submission - Investing.com
Cingulate completes pre-NDA meeting with FDA on NDA for CTx-1301 - TipRanks
Breakthrough ADHD Treatment Clears Critical FDA Hurdle: Once-Daily Drug Shows Promise - Stock Titan
Roth Capital Issues Positive Outlook for Cingulate Earnings - Defense World
Roth Capital Estimates Cingulate’s Q1 Earnings (NASDAQ:CING) - Defense World
Cingulate (CING) to Release Quarterly Earnings on Monday - Defense World
Cingulate Inc. Reports 2024 Financial and Development Milestones - TipRanks
Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved - The Manila Times
Cingulate Inc. Reports Full Year 2024, Fourth Quarter - GlobeNewswire
Cingulate's ADHD Drug Nears FDA Filing: Key Trial Results and $17.5M Cash Boost - Stock Titan
Cingulate (CING) to Release Earnings on Monday - The AM Reporter
Cingulate (CING) Expected to Announce Quarterly Earnings on Monday - Defense World
CING: April Pre-NDA Meeting - Yahoo Finance
Cingulate Inc. adjusts executive compensation - MSN
HC Wainwright Reaffirms Buy Rating for Cingulate (NASDAQ:CING) - Defense World
Promising Prospects for Cingulate Inc.: Buy Rating Backed by Positive Phase 3 Results and Market Potential of CTx-1301 - TipRanks
Breakthrough ADHD Treatment Moves Closer to FDA Approval with New Data - Streetwise Reports
Cingulate reports phase 3 safety data for CTx-1301 to treat ADHD in children, adolescents - Contemporary Pediatrics
Cingulate reports safety results from final Phase 3 trials for CTx-1301 - TipRanks
Cingulate Inc. Advances Towards FDA Approval for CTx-1301 - TipRanks
Cingulate reports promising phase 3 safety data for ADHD treatment By Investing.com - Investing.com Canada
Cingulate reports promising phase 3 safety data for ADHD treatment - Investing.com
Cingulate Reports Safety Results From Final Phase 3 Trials For Lead ADHD Asset CTX-1301 - Marketscreener.com
Cingulate Reports Safety Results from Final Phase 3 Trials - GlobeNewswire
Could This ADHD Drug Breakthrough End Multiple Daily Dosing? Cingulate's Phase 3 Results Point to Yes - StockTitan
What's Going On With Cingulate Shares Recently? - MSN
Cingulate (NASDAQ:CING) Trading Down 2.1% – Here’s Why - Defense World
Cingulate stock price target raised to $20 at H.C. Wainwright - MSN
Cingulate CEO cleared of charges, retains board confidence - Investing.com India
Cingulate CEO cleared of charges, retains board confidence By Investing.com - Investing.com Australia
Q4 Earnings Forecast for Cingulate Issued By HC Wainwright - Defense World
Cingulate Inc Azioni (CING) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.39%
3.66%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):